33,294 followers
New Research: Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind,… https://t.co/l4gsDHr9DP #Fron